tbuckley/cabot-search huggingface dataset:
Abstract 18008: Post-Transcriptional Regulation of Adiponectin by Micro-RNA 378 in Human Visceral and Subcutaneous Adipose Tissue
Authors: Masayoshi Ishida, Michio Shimabukuro, Shusuke Yagi, Daiju Fukuda, Takeshi Soeki, Hiromi Sato, Etsuko Uematsu, Hirofumi Izaki, Hiro-omi Kanayama, Masataka Sata
Journal: Circulation (2013)

Purpose: MicroRNAs (miR), single-stranded non-protein coding gene products, regulate gene expression through post-transcriptional inhibition, and involved in essential biological processes including obesity and insulin resistance. miR-378/378*, which are encoded by PGC-1β gene and counterbalance the metabolic actions of PGC-1β. We conducted to elucidate the role of miR378 expression in human adiposity and adipose tissue inflammation. Methods: Study 1 (clinical study): Pair samples were obtained from subcutaneous (SAT) and visceral adipose tissue (VAT) during elective operation in 71 men and 42 women. MiRNA and adipocytokines levels were determined by qRT-PCR. Study 2 (in vitro study): We quantitated adipocytokine transcription during adipogenesis in 3T3-L1 cells overexpressing mimics or inhibitors of miR378 and assessed post-transcriptional regulation in HEK 293 cells expressing a renilla-luciferase-adiponectin-3’UTR sequence. Results: Study 1: The mean size, median and mode of adipocytes were negatively correlated with levels of adipose adiponectin in SAT and in VAT. CD68 was negatively, and TLR4, PPARγ2, PGC-1β, and ESRRG were positively correlated with adipose adiponectin. Study 2: Upon in silico search, we found a putative target site for miRNA378/378* in the 3 prime untranslated region (3’ UTR) of adiponectin gene. Expression levels of miR378 as well as adiponectin, ACSL1, GPAT6, PPARγ2 and PGC1β were increased in 3T3L1 during differentiation. The expression of adiponectin and ESRRG, a PGC-1β partner, were inhibited by miR378 mimics. Luminescence activity in HEK 293 cells expressing a renilla-luciferase-adiponectin-3’UTR sequence was inhibited by overexpressing mimics of miR378 and the decrease was recovered by adding the inhibitors of miR378, indicating that the posttranscriptional activity of adiponectin 3’UTR of was regulated via the miR378 binding site. Conclusion: There were depot- and size-dependent variations in adiponectin, miRNA378 and its related genes in SAT and VAT. Roles of miR378 and other possible miRNAs were warranted in adiponectin expression and its post-translational modification, which links to metabolic and cardiovascular abnormalities associated with obesity and insulin resistance.
Efficacy of three-drug induction chemotherapy followed by preoperative chemoradiation in patients with localized gastric adenocarcinoma (GAC).
Authors: Dilsa Mizrak Kaya, Graciela M. Nogueras-Gonzalez, Prajnan Das, Mariela A. Blum Murphy, Fatemeh Ghazanfari Amlashi, Jane Elizabeth Rogers, Irene Thomas, Namita Shanbhag, Jeffrey H Lee, Manoop S. Bhutani, Brian Weston, Bruce D. Minsky, Aurelio Aurelio Matamoros, Tara L. Sagebiel, Catherine E Devine, Jeannelyn Estrella, Brian D. Badgwell, Jaffer A. Ajani
Journal: Journal of Clinical Oncology (2019)

106 Background: Preoperative induction chemotherapy followed by chemoradiation yields better R0 resection rates, pathologic complete response (pCR) rates and improved survival for localized GAC.Previous studies with two-drug induction chemotherapy showed 70-80% R0 resection rates and 20-30% pCR rates. We report the effect of three-drug induction chemotherapy on a large cohort of localized GAC patients. Methods: We identified 97 patients with localized GAC who received three-drug induction chemotherapy followed by preoperative chemoradiation therapy. We assessed various endpoints (overall survival [OS], recurrence-free survival [RFS], R0 resection and pCR rate). Results: The median follow-up time was 3.5 years (range; 0.4-16.7). Most of the patients were men (60.8%) and the median age was 60 years (range; 21-89). The induction chemotherapy regimen was a fluoropyrimidine and a platinum compound (cisplatin or oxaliplatin) with a taxane (docetaxel or paclitaxel) for 95% of patients. Seventy-three (75%) out of 97 patients underwent planned surgery. R0 resection and pCR rate were 93% and 21%, respectively. Pathologic partial response (&lt; 50% residual carcinoma) rate was 50.7%. The median OS was 6.43 years (95% Cl 3.27-12.36) for the entire cohort and 11.1 years (95% Cl 7.1-not estimable) for patients that underwent surgery. The estimated 2- and 5-year OS rates were 72% (95% CI 62-80) and 54% (95% CI 43-64) for the entire cohort and 83% (95% CI 72-91) and 66% (95% CI 53-76) for patients that underwent surgery. Pathological lesser stage (stage I/II vs. stage III/IV) (p = 0.001) and R0 resection (p = 0.019) were independently associated with longer RFS in the multivariate analysis. Conclusions: Our data show that three-drug combination is feasible without providing substantial advantage in this setting of preoperative induction chemotherapy followed by chemoradiation and surgery.
ATHEROSCLEROSIS IN ANCIENT AND MODERN EGYPTIANS: THE HORUS STUDY
Authors: Adel Allam, Randall Thompson, L. Samuel Wann, M. Linda Sutherland, James Sutherland, Bruno Frohlich, Michael Miyamoto, Sallam L. Sallam, MA Mandour Ali, Caleb Finch, Gregory Thomas
Journal: Journal of the American College of Cardiology (2014)
Abstract 1790: Prospective Evaluation of the Prognostic Implications of Low Level Elevation of Cardiac Troponin Using a New Highly-sensitive Assay for Cardiac Troponin I: Results from the MERLIN-TIMI 36 Trial
Authors: Marc Bonaca, Benjamin Scirica, Marc Sabatine, Anthony Dalby, Jindrich Spinar, Stacy Melanson, Petr Jarolim, David A Morrow
Journal: Circulation (2007)

Myocardial infarction (MI) is defined using a cut-point for troponin at the 99th %ile of a control population. The availability of new highly sensitive assays has raised questions as to the clinica...
Abstract P209: Dose-Response Relationship Between Dietary Intake of Alpha-linolenic Acid and Risk of Coronary Heart Disease: A Meta-analysis of Prospective Studies
Authors: Jingkai Wei, Yuzhi Xi, Ruixue Hou, Alysse Kowalski, Hao Sun, Eeshwar K Chandrasekar, Mohammed K Ali
Journal: Circulation (2017)

Introduction: Previous studies show that alpha-linolenic acid (ALA) is associated with reduced risk of coronary heart disease (CHD). However, it remains unclear whether and how dietary ALA doses are related to CHD. Hypothesis: We hypothesized that higher dietary ALA intake is associated with a greater reduction in risk of CHD. Methods: We searched PubMed, EMBASE, and Web of Science for prospective studies examining the association between dietary ALA intake and CHD risk. Dietary ALA intake was assigned or measured by self-report. Outcomes were reported as total and fatal CHD and/or myocardial infarction, which were obtained from blinded endpoint assessments or medical records. Two-stage fixed-effects dose-response meta-analyses were conducted to estimate the association between increasing ALA intake (relative to study-specific referents) and CHD. Results: Fifteen published articles were identified and included in the meta-analysis (13 cohort studies and 2 randomized controlled trials). The pooled analysis was based on 310,768 individuals with 12,049 events with a mean length of follow-up of 9.6 years. The analysis showed a J-shaped curve between ALA intake and relative risk of total CHD (Chi-square=21.08, p&lt;0.001). ALA intake from 0.3-1.4g/day showed reduced risk of total CHD, while intake ≥2.5g/day was associated with increased risk of CHD, compared to people without ALA intake (Figure 1A). Approximately 1g/day of ALA intake was associated with the lowest risk of total CHD. ALA intake was linearly associated with fatal CHD - every 1g/day increase in ALA intake was associated with an 11% decrease in fatal CHD risk (95% CI: -0.16, -0.05) (Figure 1B). Conclusion: The J-shaped dose-response relationship based on our pooled analysis suggests that 1g/day of dietary ALA may be optimal for total CHD prevention. Though a higher dietary ALA intake was associated with reduced risk of fatal CHD, the excess total CHD risk at higher ALA intakes warrants further investigation, especially through randomized controlled trials.
Neuronal Development of Hearing and Language: Cochlear Implants and Critical Periods
Authors: Andrej Kral, Michael F. Dorman, Blake S. Wilson
Journal: Annual Review of Neuroscience (2019)

The modern cochlear implant (CI) is the most successful neural prosthesis developed to date. CIs provide hearing to the profoundly hearing impaired and allow the acquisition of spoken language in children born deaf. Results from studies enabled by the CI have provided new insights into (a) minimal representations at the periphery for speech reception, (b) brain mechanisms for decoding speech presented in quiet and in acoustically adverse conditions, (c) the developmental neuroscience of language and hearing, and (d) the mechanisms and time courses of intramodal and cross-modal plasticity. Additionally, the results have underscored the interconnectedness of brain functions and the importance of top-down processes in perception and learning. The findings are described in this review with emphasis on the developing brain and the acquisition of hearing and spoken language.
ERAP1 allotypes shape the epitope repertoire of virus-specific CD8+ T cell responses in acute hepatitis C virus infection
Authors: Janine Kemming, Emma Reeves, Katja Nitschke, Vanessa Widmeier, Florian Emmerich, Tobias Hermle, Emma Gostick, Andreas Walker, Jörg Timm, David A. Price, Maike Hofmann, Robert Thimme, Edward James, Christoph Neumann-Haefelin
Journal: Journal of Hepatology (2019)

Endoplasmic reticulum aminopeptidase 1 (ERAP1) polymorphisms are linked with human leukocyte antigen (HLA) class I-associated autoinflammatory disorders, including ankylosing spondylitis and Behçet's disease. Disease-associated ERAP1 allotypes exhibit distinct functional properties, but it remains unclear how differential peptide trimming in vivo affects the repertoire of epitopes presented to CD8+ T cells. The aim of this study was to determine the impact of ERAP1 allotypes on the virus-specific CD8+ T cell epitope repertoire in an HLA-B*27:05+ individual with acute hepatitis C virus (HCV) infection.We performed genetic and functional analyses of ERAP1 allotypes and characterized the HCV-specific CD8+ T cell repertoire at the level of fine epitope specificity and HLA class I restriction, in a patient who had acquired an HCV genotype 1a infection through a needle-stick injury.Two hypoactive allotypic variants of ERAP1 were identified in an individual with acute HCV infection. The associated repertoire of virus-derived epitopes recognized by CD8+ T cells was uncommon in a couple of respects. Firstly, reactivity was directed away from classically immunodominant epitopes, preferentially targeting either novel or subdominant epitopes. Secondly, reactivity was biased towards longer epitopes (10-11-mers). Despite the patient exhibiting favorable prognostic indicators, these atypical immune responses failed to clear the virus and the patient developed persistent low-level infection with HCV.ERAP1 allotypes modify the virus-specific CD8+ T cell epitope repertoire in vivo, leading to altered immunodominance patterns that may contribute to the failure of antiviral immunity after infection with HCV.Endoplasmic reticulum aminopeptidase 1 (ERAP1) plays a key role in antigen presentation. Genetic variants of ERAP1 (leading to distinct allotypes) are linked with specific autoinflammatory disorders, such as ankylosing spondylitis and Behçet's disease. We found that ERAP1 allotypes modified the repertoire of virus-specific CD8+ T cell epitopes in a patient with hepatitis C virus, leading to an altered pattern of immunodominance that may have contributed to the failure of antiviral immunity in this patient.
Leiomodin-3 dysfunction results in thin filament disorganization and nemaline myopathy
Authors: Michaela Yuen, Sarah A. Sandaradura, James J. Dowling, Alla S. Kostyukova, Natalia Moroz, Kate G. Quinlan, Vilma-Lotta Lehtokari, Gianina Ravenscroft, Emily J. Todd, Ozge Ceyhan-Birsoy, David S. Gokhin, Jérome Maluenda, Monkol Lek, Flora Nolent, Christopher T. Pappas, Stefanie M. Novak, Adele D’Amico, Edoardo Malfatti, Brett P. Thomas, Stacey B. Gabriel, Namrata Gupta, Mark J. Daly, Biljana Ilkovski, Peter J. Houweling, Ann E. Davidson, Lindsay C. Swanson, Catherine A. Brownstein, Vandana A. Gupta, Livija Medne, Patrick Shannon, Nicole Martin, David P. Bick, Anders Flisberg, Eva Holmberg, Peter Van den Bergh, Pablo Lapunzina, Leigh B. Waddell, Darcée D. Sloboda, Enrico Bertini, David Chitayat, William R. Telfer, Annie Laquerrière, Carol C. Gregorio, Coen A.C. Ottenheijm, Carsten G. Bönnemann, Katarina Pelin, Alan H. Beggs, Yukiko K. Hayashi, Norma B. Romero, Nigel G. Laing, Ichizo Nishino, Carina Wallgren-Pettersson, Judith Melki, Velia M. Fowler, Daniel G. MacArthur, Kathryn N. North, Nigel F. Clarke
Journal: Journal of Clinical Investigation (2015)
Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database
Authors: Laurent Arnaud, Philippe Mertz, Pierre-Edouard Gavand, Thierry Martin, François Chasset, Martine Tebacher-Alt, Aude Lambert, Charlotte Muller, Jean Sibilia, Bénédicte Lebrun-Vignes, Joe-Elie Salem
Journal: Annals of the Rheumatic Diseases (2019)

Objective Drug-induced lupus (DIL) is an idiosyncratic side effect of treatments in which symptoms overlap with those of systemic lupus erythematosus (SLE). The spectrum of DIL constantly evolves with that of the pharmacopoeia. Here, we used VigiBase, the WHO global individual case safety reports (ICSRs) database, to identify the main drugs associated with DIL. Methods We analysed all ICSRs classified as ‘systemic lupus erythematosus’ according to the Medical Dictionary for Drug Regulatory Activities term (preferred term level) in VigiBase. The drugs considered in the analysis were those not used to treat SLE, with a positive lower end of the 95% credibility interval for the information component (IC 025 ) ≥0, an indicator value for disproportionate Bayesian reporting. Results A total of 12 166 DIL ICSRs were identified using VigiBase. From those, 8163 ICSRs reporting on 118 suspected drugs with IC 025 ≥0 were extracted. The median age at DIL onset was 49 years and the female to male sex ratio was 4.3. The median delay between start of suspected treatment and DIL occurrence was 172 days. DIL was reported as serious adverse event in 55.4%. Among the 118 suspected drugs, 42 had not been previously reported in association with DIL. The drugs associated with the highest number of DIL cases were infliximab, adalimumab, etanercept, procainamide and hydralazine. Conclusion This study enables the identification of 118 drugs associated with DIL. The list of suspected drugs may prove useful to physicians when confronted with potential DIL cases. Trial registration number NCT03480529 .
Abstract 15597: Transvascular Mechanical Unloading Combined With Ivabradine Stabilizes Hemodynamics and Strikingly Suppresses the Infarct Size in Acute Myocardial Infarction
Authors: Genya Sunagawa, Keita Saku, Takahiro Arimura, Takuya Akashi, Yoshinori Murayama, Takafumi Sakamoto, Takuya Kishi, Tomomi Ide, Hiroyuki Tsutsui, Kenji Sunagawa
Journal: Circulation (2016)

Background: Myocardial infarction (MI) remains a leading cause of chronic heart failure (CHF) despite the latest advances of early reperfusion. The presence of unsalvaged myocardium leads to cardia...
Indeterminate Pulmonary Nodules at Diagnosis in Rhabdomyosarcoma: Are They Clinically Significant? A Report From the European Paediatric Soft Tissue Sarcoma Study Group
Authors: Bas Vaarwerk, Gianni Bisogno, Kieran McHugh, Hervé J. Brisse, Carlo Morosi, Nadège Corradini, Meriel Jenney, Daniel Orbach, Julia C. Chisholm, Andrea Ferrari, Ilaria Zanetti, Gian Luca De Salvo, Rick R. van Rijn, Johannes H.M. Merks
Journal: Journal of Clinical Oncology (2019)

Purpose To evaluate the clinical significance of indeterminate pulmonary nodules at diagnosis (defined as ≤ 4 pulmonary nodules &lt; 5 mm or 1 nodule measuring ≥ 5 and &lt; 10 mm) in patients with pediatric rhabdomyosarcoma (RMS). Patients and Methods We selected patients with supposed nonmetastatic RMS treated in large pediatric oncology centers in the United Kingdom, France, Italy, and the Netherlands, who were enrolled in the European Soft Tissue Sarcoma Study Group (E pSSG) RMS 2005 study. Patients included in the current study received a diagnosis between September 2005 and December 2013, and had chest computed tomography scans available for review that were done at time of diagnosis. Local radiologists were asked to review the chest computed tomography scans for the presence of pulmonary nodules and to record their findings on a standardized case report form. In the E pSSG RMS 2005 Study, patients with indeterminate pulmonary nodules were treated identically to patients without pulmonary nodules, enabling us to compare event-free survival and overall survival between groups by log-rank test. Results In total, 316 patients were included; 67 patients (21.2%) had indeterminate pulmonary nodules on imaging and 249 patients (78.8%) had no pulmonary nodules evident at diagnosis. Median follow-up for survivors (n = 258) was 75.1 months; respective 5-year event-free survival and overall survival rates (95% CI) were 77.0% (64.8% to 85.5%) and 82.0% (69.7% to 89.6%) for patients with indeterminate nodules and 73.2% (67.1% to 78.3%) and 80.8% (75.1% to 85.3%) for patients without nodules at diagnosis ( P = .68 and .76, respectively). Conclusion Our study demonstrated that indeterminate pulmonary nodules at diagnosis do not affect outcome in patients with otherwise localized RMS. There is no need to biopsy or upstage patients with RMS who have indeterminate pulmonary nodules at diagnosis.
The Best Medicine
Authors: Gregory A. Abel
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Fixing the Problem of Discard of Livers From Older Donors
Authors: Seth A. Waits, Michael J. Englesbe
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Reply to Steven C. Campbell, Chalairat Suk-Ouichai, and Yun-Lin Ye's Words of Wisdom re: Below Safety Limits, Every Unit of Glomerular Filtration Rate Counts: Assessing the Relationship between Renal Function and Cancer-specific Mortality in Renal Cell Carcinoma. Antonelli A, Minervini A, Sandri M, et al. Eur Urol 2018;74:661–7 and 2019;75:198
Authors: Alessandro Antonelli, Andrea Minervini, Umberto Capitanio
Journal: European Urology (2019)
Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment
Authors: Eric J Chow, Kasey J Leger, Neel S Bhatt, Daniel A Mulrooney, Colin J Ross, Sanjeev Aggarwal, Neha Bansal, Matthew J Ehrhardt, Saro H Armenian, Jessica M Scott, Borah Hong
Journal: Cardiovascular Research (2019)

With 5-year survival of children with cancer exceeding 80% in developed countries, premature cardiovascular disease is now a major cause of early morbidity and mortality. In addition to the acute and chronic cardiotoxic effects of anthracyclines, related chemotherapeutics, and radiation, a growing number of new molecular targeted agents may also have detrimental effects on the cardiovascular system. Survivors of childhood cancer also may have earlier development of conventional cardiovascular risk factors such as hypertension, dyslipidaemia, and diabetes, which further increase their risk of serious cardiovascular disease. This review will examine the epidemiology of acute and chronic cardiotoxicity relevant to paediatric cancer patients, including genetic risk factors. We will also provide an overview of current screening recommendations, including the evidence regarding both imaging (e.g. echocardiography and magnetic resonance imaging) and blood-based biomarkers. Various primary and secondary prevention strategies will also be discussed, primarily in relation to anthracycline-related cardiomyopathy. Finally, we review the available evidence related to the management of systolic and diastolic dysfunction in paediatric cancer patients and childhood cancer survivors.
Scratching the Endometrium in In Vitro Fertilization — Time to Stop
Authors: Ben W. Mol, Kurt T. Barnhart
Journal: New England Journal of Medicine (2019)

Infertility, the inability to achieve a pregnancy after 12 months of unprotected intercourse, affects 1 in 10 couples and is fraught with frustration, anxiety, and a strong desire for success. Despite continual advances in techniques and technology since the introduction of in vitro fertilization (IVF) more than 40 years ago,1 this approach is successful in fewer than half of initiated cycles. In an effort to improve success, various modifications or adjuvants to IVF are offered to patients, despite an absence of regulatory approval and a lack of data to support their effectiveness. A recent review of 27 adjuvant techniques used . . .